

ONE HUNDRED FOURTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927
Minority (202) 225-3641

November 24, 2015

Mr. Jack Riley
Deputy Administrator
Drug Enforcement Administration
U.S. Department of Justice
8701 Morrisette Drive
Springfield, VA 22152

Dear Mr. Riley:


Thank you for appearing before the Subcommittee on Health on October 8, 2015, to testify at the hearing entitled "Examining Legislative Proposals to Combat Our Nation's Drug Abuse Crisis."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on December 8, 2015. Your responses should be mailed to Graham Pittman, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to graham.pittman@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,


Joseph R. Pitts
Chairman
Subcommittee on Health

cc: The Honorable Gene Green, Ranking Member, Subcommittee on Health

Attachment

Attachment — Additional Questions for the Record

The Honorable Representative Joseph R. Pitts

1. What efforts are underway at the DEA to work with HHS to combat this national epidemic?
2. How are you coordinating with other agencies?

The Honorable Representative Tim Murphy

1. How great is the risk of diversion of buprenorphine? Is it different from the risks of diversion among other prescription drugs?
2. In your view, how important is it that medication-assisted treatments be accompanied by behavioral counseling and psycho-social support?

The Honorable Representative Frank Pallone, Jr.

The Controlled Substances Act currently prohibits the transportation of controlled substances outside of registered locations, making it illegal for physicians to transport controlled substances from one practice setting to another. I have heard from sports medicine physicians and others about the need to transport controlled substances from one state to another for an athletic game or tournament, but also in instances of a major disaster.

1. It is important that legislation that would help to address the issue sports medicine physicians face also strikes an appropriate balance so as to protect against theft or diversion. In your opinion, what safeguards could be put in place to allow for the safe transport of controlled substances in limited situations?